Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more
Mediwound Ltd (MDWD) - Total Liabilities
Latest total liabilities as of September 2025: $34.98 Million USD
Based on the latest financial reports, Mediwound Ltd (MDWD) has total liabilities worth $34.98 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mediwound Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Mediwound Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mediwound Ltd Competitors by Total Liabilities
The table below lists competitors of Mediwound Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cairn Energy PLC
PINK:CRNZF
|
USA | $188.60 Million |
|
Equity Commonwealth
NYSE:EQC
|
USA | $51.16 Million |
|
China Aircraft Leasing Group Holdings Limited
PINK:CFRLF
|
USA | $52.79 Billion |
|
MK Restaurant Group Public Company Limited
BK:M
|
Thailand | ฿5.74 Billion |
|
KDDL Limited
NSE:KDDL
|
India | ₹7.97 Billion |
|
Wheeler Real Estate Investment Trust Inc. 7.00% Senior Subordinated Convertible Notes Due 2031
NASDAQ:WHLRL
|
USA | $534.62 Million |
|
Materialise NV
NASDAQ:MTLS
|
USA | $164.14 Million |
|
Copley Acquisition Corp
NYSE:COPL
|
USA | $5.35 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Mediwound Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mediwound Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mediwound Ltd (2012–2024)
The table below shows the annual total liabilities of Mediwound Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $42.34 Million | +21.45% |
| 2023-12-31 | $34.86 Million | -10.84% |
| 2022-12-31 | $39.10 Million | +60.74% |
| 2021-12-31 | $24.33 Million | +2.22% |
| 2020-12-31 | $23.80 Million | -6.38% |
| 2019-12-31 | $25.42 Million | -3.36% |
| 2018-12-31 | $26.30 Million | -23.79% |
| 2017-12-31 | $34.52 Million | +23.29% |
| 2016-12-31 | $27.99 Million | -3.65% |
| 2015-12-31 | $29.05 Million | +2.84% |
| 2014-12-31 | $28.25 Million | -18.42% |
| 2013-12-31 | $34.63 Million | +253.22% |
| 2012-12-31 | $9.80 Million | -- |